1203 results about "Adenosine" patented technology

Compositions and methods for editing deleterious mutations associated with Alpha-1 Antitrypsin Deficiency (A1AD). In particular embodiments, the invention provides methods for treating A1AD using a modified adenosine base editor with improved on-target editing and decreased off-target editing to correct mutations associated with A1AD.

The invention discloses an S-adenosylmethionine synthetase mutant and application thereof, and belongs to the field of gene engineering and fermentation engineering. The site 189, the site 200, the site 234, the site 266, the site 370 and the site 371 of the S-adenosylmethionine synthetase MAT are subjected to site-specific combinatorial mutation, a series of mutants with improved enzyme activity are obtained, the enzyme activity of N371R is improved to the maximum extent, and the specific enzyme activity is 1.2128 + / -0.0423 U.mg <-1 > and is 4.91 times that of WT. The enzyme mutant provided by the invention has a wide application prospect in the production of S-adenosylmethionine and the construction of genetic engineering microorganisms of S-adenosylmethionine.

Among other things, the present disclosure provides oligonucleotides, compositions and methods thereof that can bring about specific editing of a target adenosine in a target RNA molecule. Such oligonucleotides, compositions and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders, diseases and syndromes that can benefit from adenosine modification.

The present disclosure features useful oligonucleotide compositions and methods related thereto. The present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g. modifications of sugar, base and / or internucleotide linkages) or patterns thereof, can have a significant impact on oligonucleotide properties and activities. The present disclosure also provides methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.

Provided are S-adenosylmethionine synthetase mutants and the use thereof, belonging to the technical field of biological enzyme engineering. Site-directed combinatorial mutations are performed on positions 189, 200, 234, 266 and 371 of S-adenosylmethionine synthetase MAT to obtain a series of mutants with improved enzyme activity, wherein the specific enzyme activity of I189V / V266H and V266H / N371R is increased by more than 10 times relative to the parent. The yields of S-adenosylmethionine synthesized by whole cells of recombinant bacteria expressing mutants I189V / V266H / N371R, V266H / Q234N / N371R and I189V / V266H / Q234N / N371R all reach 1550 mg / L or more. The provided enzyme mutants have broad application prospects in the production of S-adenosylmethionine and the construction of genetically engineered microorganisms for S-adenosylmethionine.

Provided are an adenosine triphosphatase sarcoplasmic / endoplasmic reticulum Ca2+ transporting 2 (ATP2A2) gene-based molecular marker for identifying a chicken feed efficiency trait, and an identification method and use thereof. A nucleotide sequence of the molecular marker is shown in SEQ ID NO: 1, and a base at locus 926 in the nucleotide sequence is T or G. In the present application, by identifying a genotype of the molecular marker in a chicken genome and then selecting the chicken feed efficiency trait according to the genotype, a breeding method for early selection of the poultry feed efficiency trait is established. The method is simple, rapid, and low-cost, does not require special instruments, and is suitable for the needs of marker-assisted selection experiments.

The invention provides an adenosine dihydroxysuccinate eutectic crystal and a preparation method and application thereof.In the adenosine dihydroxysuccinate eutectic crystal, the molar ratio of a dihydroxysuccinic acid molecule to an adenosine molecule is 1: (1-4), on the premise that the structure of adenosine is not changed, dihydroxysuccinic acid and adenosine are combined, the water solubility of adenosine is improved, and therefore the adenosine dihydroxysuccinate eutectic crystal is obtained. According to the preparation method, the adenosine which is difficult to dissolve in water is prepared into the water-soluble adenosine dihydroxysuccinate eutectic crystal, so that the water solubility of the adenosine dihydroxysuccinate eutectic crystal can reach 4%, the effects of the adenosine dihydroxysuccinate and the adenosine monomer are not damaged, and the adenosine dihydroxysuccinate and the adenosine monomer have a better synergistic effect; compared with a monomer and a simple mixture, the composition has better effects in the aspects of antibiosis, antioxidation, anti-aging, hair care, hair loss prevention and the like, and has a good application prospect in skin and hair care products.

There is provided a fluorinase variant thereof having at least 70% sequence identity to a sequence MSDLGX6TDDSVAQCKGLMLSICPX24VX26IX28DX30CHX33MTPX37DVVEGARYIVDLPR X52FPEGTVFATTTYPATGTX70X71RSVAX76RX78KX80AALGGARGQX90AGSGX95GX97E RAEGX103YIYIAPNNGLLTX116VIEEHGYX124EAYEVSX131TX133VIPX137X138PEPTFYSR EMVAIPSAHLAAGFPLX163X164VGRX168LX170DX172EIVRFEX179X180KX182X183X184VX186G X188X189LX191GX193X194X195X196X197DHPFGNX204WTNX208HRTDLEKAGIX219YX221TX223X 224KX226VX228DGVLX233FX235LPLX239PTFADAX246X247X248GX250PVX253YX255NSRGYLX2 62X263ARNAAX269LAYPYNLX277AGX280SVX283VTX286A (SEQ ID NO: 1), wherein X is a natural amino acid, and wherein the variant comprises one or more mutations at a site selected from the group consisting of an ion-egress site, a S-Adenosyl-L-Methionine (SAM) binding site, an ion-binding site (IBS), and a conserved site. Also disclosed are polynucleotides encoding the variants, vectors comprising the polynucleotides encoding the variants, and host cells comprising the vectors thereof. Also disclosed are Methods for producing the variants, methods of catalyzing the fluorination of a compound, uses of the fluorinase variants, and methods of treatment using the fluorinase variants thereof.

The invention relates to the technical field of biology, and provides a probiotic composition for relieving sarcopenia obesity and application of the probiotic composition. The composition comprises at least two of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Wherein the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.25839; the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.26968; the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC (China General Microbiological Culture Collection Center) No. 27998. The composition disclosed by the invention can be used for increasing the muscle content of an organism, improving the muscle tissue form, increasing adenosine triphosphate and inhibiting abnormal increase of body weight, so that the composition can be used for effectively preventing and treating sarcopenia obesity.

The invention discloses a compound with a heteroaromatic ring sulfonamide structure as well as a pharmaceutical composition and application thereof. The invention provides a compound with a heteroaromatic ring sulfonamide structure as shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, tautomers or isotope compounds thereof. The compound with the heteroaromatic ring sulfonamide structure is expected to be used for treating and / or preventing various diseases related to poly adenosine diphosphate ribose hydrolase (PARG). # imgabs0 #

The invention discloses a preparation method and application of a recombinant XVII type collagen and adenosine eutectic substance. According to the invention, adenosine and recombinant XVII type collagen are combined through a non-covalent bond to form a novel supramolecular eutectic substance. The solubility and skin permeability of the eutectic substance are improved through the synergistic effect of the two substances, and the performance of fixing hair and promoting hair papilla cell proliferation is also enhanced.

The invention discloses a mutant with improved catalytic activity of S-adenosylmethionine synthetase and application of the mutant, and belongs to the technical field of biological enzyme engineering. According to the present invention, the site 189, the site 234, the site 266 and the site 371 of the S-adenosylmethionine synthetase MAT are subjected to site-specific combinatorial mutation to obtain a series of mutants with improved enzyme activity, the I189V / V266H improvement is the most obvious, and the specific enzyme activity is 3.5833 + / -0.1373 U.mg <-1 >, which is improved by 1353.08% compared to the parent WT; and for a whole-cell catalysis system, the yield of S-ademetionine synthesized by the mutant I189V / V266H / Q234N / N371R reaches 1751.01 mg / L, and the increase is most obvious. The enzyme mutant provided by the invention has a wide application prospect in the production of S-adenosylmethionine and the construction of genetic engineering microorganisms of S-adenosylmethionine.

The invention relates to an insect adenosine triphosphate binding cassette superfamily transport protein and application thereof. The insect adenosine triphosphate binding cassette superfamily transporter is a homodimer, and each monomer has an adenosine triphosphate binding and hydrolysis structural domain, a transmembrane structural domain containing 6 transmembrane helixes and an extracellular structural domain; in a transmembrane structure domain of the protein structure, a spiral 1, a spiral 2 and a spiral 5 of each monomer form an arched substrate binding channel. Experiments show that the adenosine triphosphate binding cassette superfamily transporter and a pesticide micromolecule substrate are bound in the arched substrate binding channel and are discharged out of a body, so that drug resistance is generated, and the transport protein can be used for treating the pesticide micromolecule substrate. Therefore, the insect adenosine triphosphate binding cassette superfamily transport protein can be used as a target of insecticide resistance so as to design an efficient inhibitor compound, and can be used as a target spot for solving the insecticide resistance.

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.

The invention discloses a novel biosynthesis path for producing 3 '-phosphoadenosine-5'-phosphosulfuric acid and application, and belongs to the technical field of bioengineering. According to the invention, through recombinant expression and purification of ribose kinase, ribose phosphate pyrophosphate kinase, ribose phosphate transferase, adenine thiotransferase, adenosine phosphate sulfate kinase and polyphosphate kinase 2, a six-enzyme cascade reaction taking ribose and adenosine as substrates in vitro is constructed, the molar conversion rate reaches 22.85%, and the escherichia coli and bacillus subtilis PAPS cell factory can be used for preparing the recombinant ribose phosphate pyrophosphate kinase, the ribose phosphate transferase, the adenine thiotransferase, the adenosine phosphate sulfate kinase and the polyphosphate kinase 2. The yield of PAPS in a 5-L fermentation tank reaches 7.60 g / L and 5.03 g / L respectively. The PAPS synthesis route provided by the invention provides an extensible, economical and efficient solution for the production of sulfated compounds.

The invention discloses a variable polyadenylation dynamic analysis method and device. The method comprises the following steps: acquiring initial space transcriptome data and an initial space bright field image; performing first preprocessing on the initial space transcriptome data to obtain target space transcriptome data; performing second preprocessing on the initial space bright field image to obtain a target space bright field image; performing data analysis and integration processing to obtain spatial variable polyadenylation data, spatial gene expression data and spatial cell distribution dynamic data; constructing a gene expression regulation network; generating an integrated analysis result; performing space-time analysis to obtain a space-time analysis result; performing trajectory analysis to obtain a trajectory analysis result; performing disease process analysis to obtain a disease process analysis result; and generating a variable poly-adenosine acidification dynamic analysis result. According to the invention, dynamic analysis of variable polyadenylation is realized, the accuracy is improved, and multi-angle biological understanding is provided. The method can be applied to the technical field of gene analysis.

The present disclosure features useful compositions and methods to treat disorders (e.g., alpha-1-antitrypsin deficiency) for which deamination of an adenosine in an mRNA produces a therapeutic result in a subject in need thereof.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention belongs to the field of biological catalysis, and particularly relates to a method for preparing oxidized nicotinamide adenine dinucleotide phosphate through double-enzyme coupling. According to the invention, through construction and optimization of a one-pot double-enzyme coupled catalytic system, a genetically engineered bacterium containing nicotinamide mononucleotide adenosine transferase NMNAT and a genetically engineered bacterium containing NAD kinase are used as a whole-cell catalyst, nicotinamide mononucleotide NMN is used as a starting substrate, adenosine triphosphate, polyphosphate and divalent metal ion salt are added, and the whole-cell enzyme is prepared through a one-pot method. The oxidized nicotinamide adenine dinucleotide phosphate NADP < + > is efficiently and catalytically synthesized by a one-pot method, and the whole-cell catalytic reaction liquid is separated and purified to obtain the NADP < + >. The double-enzyme catalysis method disclosed by the invention is short in reaction route, high in atom economy, capable of reducing the existing production cost, short in production period, easy for downstream separation and purification, and suitable for large-scale and large-scale production of NADP < + >.

The invention discloses an adenosine kinase mutant with high thermal stability and application thereof, and relates to the technical field of enzyme engineering, and the adenosine kinase mutant with high thermal stability is obtained by performing point mutation on the 253rd site or the 82nd site of adenosine kinase as shown in SEQ ID NO: 1. According to the invention, an adenosine kinase mutant is used as a biocatalyst in an enzyme catalysis manner; the method is used for enzymatic synthesis of 5 '-adenylic acid, adenosine and adenosine triphosphate react to prepare adenylic acid, generation of by-products and impurities in the reaction is reduced to a certain extent, production efficiency and purity of adenylic acid are improved, reaction conditions are mild in preparation in an enzyme catalysis mode, pollution to the environment is avoided, and the method is suitable for industrial production. And the high-thermal-stability adenosine kinase mutant is applied to adenylic acid preparation, so that the preparation efficiency and yield of adenylic acid can be improved.

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, the present disclosure provides oligonucleotide compositions that can edit an adenosine in a PNPLA3 transcript. In some embodiments, the present disclosure provides methods for preventing or treating conditions, disorders or diseases, e.g., those that can benefit from editing of an adenosine in a PNPLA3 transcript.

The invention relates to the technical field of diagnosis markers and diagnosis methods for mental diseases of children and adolescents, in particular to a plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents. The plasma metabolism diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenyl carnitine, histidine, prolyl hydroxyproline, tryptophan and glucuronic acid. According to the scheme, non-target metabonomics data is analyzed, and seven candidate diagnostic markers for depression of children and adolescents are screened and determined from common differential metabolites. Then, through targeted metabonomics research, diagnostic markers and combinations thereof with ideal diagnostic effects are determined, and then a diagnostic model is constructed. And a sex factor is also incorporated into the diagnosis model, so that the diagnosis effect is further improved. According to the technical scheme, the technical problem that in the prior art, reliability and popularization potential of depression plasma metabolism biomarkers of children and adolescents are not ideal can be solved, and the depression plasma metabolism biomarkers have ideal popularization and application prospects.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and / or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and / or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin− and / or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and / or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and / or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

The invention discloses a method for efficiently producing ergothioneine by metabolic engineering modified escherichia coli and application, and belongs to the technical field of biology. By adopting the recombinant escherichia coli EGT-1-B * provided by the invention, glucose can be converted into ergothioneine; therefore, the raw materials are cheap and easy to obtain, additives and heavy metals which are harmful to human health are avoided, a good foundation is laid for later product purification, and the requirements of commercial application can be met. Furthermore, genes related to metabolism of histidine, methionine, cysteine and S-adenosylmethionine are further overexpressed in the recombinant escherichia coli EGT-1-B *, so that the content of precursor amino acid synthesized by the ergothioneine is increased, and meanwhile, after the gene yqaB is knocked out, the yield of the ergothioneine is further increased; the utilization rate of glucose to ergothioneine can be further improved, and the yield of ergothioneine can reach 140.29 mg / L.

Among other things, the present disclosure provides oligonucleotides, compositions and methods thereof that are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.

The invention discloses an anti-aging composition derived from space breeding desert algae as well as a preparation method and application of the anti-aging composition, and relates to the technical field of application of desert algae. The anti-aging composition is an extract of Hassalliasp.P06 after space breeding, and the preservation number of the Hassalliasp.P06 is CCTCC (China Center for Type Culture Collection) M20242054, and the preservation number of the Hassalliasp.P06 is CCTCC M20242054. The anti-aging composition derived from the space breeding desert algae comprises the following components: polypeptide, free amino acid, polysaccharide and cyclic adenosine monophosphate. The skin care product has very strong moisturizing capacity, can promote the proliferation of skin fibroblasts and remarkably improve the skin compactness, has a soothing effect and oxidation resistance, and can be applied to skin care products or cosmetics to be used as a compactness agent or an anti-aging agent so as to improve the skin aging symptom.

A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a methionine adenosyltransferase IIα (MAT2A) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or MAT2A.

The present application relates to compounds of formula (I), and their pharmaceutical compositions / preparations. This application further relates to methods of treating Rett syndrome and / or one or more symptoms associated with Rett syndrome, FOXG1 syndrome and / or one or more symptoms associated with FOXG1 syndrome, CDKL5 deficiency disorder (CDD) and / or one or more symptoms associated with CDD, or CHD8-related neurodevelopmental disorder (CHD8-NDD) and / or one or more symptoms associated with CHD8-NDD, chronic heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), or heart failure with mid-range ejection fraction (HFmrEF).

The invention discloses a hair-fixing and hair-loss-preventing composition, application thereof and a hair-fixing and hair-loss-preventing product. The hair fixing and hair loss preventing composition comprises 17-type collagen, a plant extract and adenosine substances, wherein the plant extract comprises a cacumen biotae extract. On the basis of inhibiting 5alpha-reductase and resisting oxidation, the composition disclosed by the invention also has the effects of fixing hair and preventing hair loss by virtue of ways of relieving inflammatory response, activating hair papilla cells, maintaining health of the hair papilla cells, reducing hair follicle senescence cells and the like.

The invention provides an anti-hair-loss and hair-growing product containing plant extract components and a preparation method thereof, and relates to the field of wash supplies, the anti-hair-loss and hair-growing product is prepared from the following raw materials by weight: 50-80 parts of water, 5-10 parts of propylene glycol, 1-5 parts of 1, 3-propylene glycol, 1-5 parts of 1, 3-propylene glycol, and 1-5 parts of 1, 3-propylene glycol. The composition is prepared from the following components in parts by weight: 0.1 to 1 part of 1, 2-pentanediol, 0.1 to 1 part of pyrrolidinyl diaminopyrimidine oxide, 0.1 to 0.5 part of diaminopyrimidine oxide, 0.01 to 0.02 part of caffeine, 0.01 to 0.1 part of adenosine, 0.05 to 0.2 part of vitamin B6, 0.01 to 0.5 part of biotin tripeptide-1, 0.1 to 1 part of dipotassium glycyrrhizinate, 0.02 to 0.05 part of ethylenediamine tetraacetic acid, 0.1 to 1 part of D panthenol, 0.2 to 1 part of p-hydroxyacetophenone, 0.01 to 1 part of 1, 2-pentanediol, 0.1 to 1 part of 1, 2-pentanediol, 0.1 to 1 part of 2, 2-pentanediol, 0.1 to 1 part of 2, 2-pentanediol, 0.1 to 1 part of 2, 2- The composition comprises the following components in parts by weight: 1-2 parts of 1, 2-hexanediol, 0.1-0.5 part of citric acid, 1-2 parts of 1, 3-butanediol, 0.01-1 part of NMN and 3-5 parts of a plant extract. According to the present invention, the extraction method of the plant extract in the raw materials is specifically adjusted so as to significantly reduce the content of the pigment and the odor substance in the extract, such that the obtained hair growing liquid has characteristics of good hair growing effect, light color and light drug taste, can be easily accepted by consumers, and is suitable for large-scale promotion and application.